Royalty Report: Drugs, Disease, Cancer – Collection: 294260

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 15

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 15

Primary Industries

  • Drugs
  • Disease
  • Cancer
  • Delivery
  • Nanoparticles
  • DNA
  • Cannabis
  • Drug Discovery
  • Pharmaceuticals
  • cardiac
  • Diagnostic
  • Therapeutic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 294260

License Grant
Licensor grants to Licensee, and Licensee accepts, the exclusive right and exclusive license under the Licensed Technology within the Field throughout the Territory (with the right to grant sublicenses), to research, develop, manufacture, have manufactured, market, export, have exported, import, use, offer for sale, sell, have sold, distribute, promote, detail, and otherwise commercialize the Licensed Compound or Products. The license is exclusive (even as to Licensor)
License Property
Licensed Compound means all forms of MB6866  (at  times known as remofovir and now known as pradefovir) including any complexes, chelates, clathrates, acids, bases, esters, salts, isomers, stereoisomers, enantiomers, pro-drug form, metabolite, hydrate, solvate, polymorph, and crystalline forms thereof, or any Substitute Compound substituted in accordance with the Original Agreement, and its various forms including salts and prodrugs.

Product means any human pharmaceutical product in finished pharmaceutical form containing, in whole or as a component, the Licensed Compound.

Licensed Technology means the Licensed Know-How. Licensed Know-How means any Know-How Controlled by Licensor as of the Effective Date or thereafter during the Term relating to the Licensed Compound that is reasonably necessary or useful to research, develop, prepare, make, have made, market, export, have exported, import, use, offer for sale, sell, have sold, distribute, promote, detail or otherwise commercialize a Licensed Compound or Product in the Field in the Territory.

Field of Use
Pradefovir compound is an oral once-a-day monotherapy for patients with chronic hepatitis B infection. The active molecule in this compound exhibits anti-hepatitis B activity against both the wild type and lamivudine drug-resistant hepatitis B. We completed Phase 1 and Phase 2 clinical trials of pradefovir.

IPSCIO Record ID: 273416

License Grant
Licensor grants to Licensee and Licensee accepts, the exclusive right and exclusive license under the Licensed Patents and the Licensed Technology within the Field throughout the Territory (with the right to grant sublicenses), to research, develop, manufacture, have manufactured, market, export, have exported, import, use, offer for sale, sell, have sold, distribute, promote, detail, and otherwise commercialize the Licensed Compound or Products.  The license is exclusive (even as to Licensor) with respect to the Licensed Patents and with respect to the Licensed Technology.  This does not prevent Licensor from granting licenses to Third Parties with respect to compounds or products that do not fall within the definition herein of Licensed Compounds or Products.
License Property
Product means any human pharmaceutical product in finished pharmaceutical form containing, in whole or as a component, the Licensed Compound.

Licensed Patents means any and all Patent Rights which Licensor Controls in any country of the Territory, having one or more Valid Claims Covering the Licensed Compound or Product in the Field and which are reasonably necessary or useful to research, develop, prepare, make, have made, market, export, have exported, import, use, offer for sale, sell, have sold, distribute, promote, detail or otherwise commercialize a Licensed Compound or Product in the Field in the Territory.  Licensed Patents includes the Patent Rights set forth below
U.S. Patent 6312662 – Prodrugs phosphorus-containing compounds
U.S. Patent 6946115 – Prodrugs for phosphorus-containing compounds
U.S. Patent 6752981 – Prodrugs for liver specific drug delivery

Licensed Technology means all HepDirect Technology on the Closing Date or during the Term, which are necessary or useful to research, develop, prepare, make, have made, market, export, have exported, import, use, offer for sale, sell, have sold, distribute, promote, detail or otherwise commercialize a Licensed Compound or Product in the Field in the Territory.  By way of clarification, Licensed Technology includes all such HepDirect Technology conceived or acquired in whole or in part by Licnesor on or after the Closing Date including the items set forth in the agreement.

Licensed Compound means all forms of MB6866 as identified (at times known as remofovir and now known as pradefovir) including any complexes, chelates, clathrates, acids, bases, esters, salts, isomers, stereoisomers, enantiomers, pro-drug form, metabolite, hydrate, solvate, polymorph, and crystalline forms thereof, or any Substitute Compound substituted in accordance with Article III, and its various forms including salts and prodrugs.

Field of Use
MB6866 is a novel oral drug for Hepatitis B.

IPSCIO Record ID: 273379

License Grant
The Irish Licensor grants to the Irish Licensee an exclusive license to the Licensor Intellectual Property to import, export, use, other than for formulation development activities, offer for sale and sell the Product in the Field in the Territory.

Licensor grants a worldwide, non-exclusive license to the Licensor Trademark, solely for the purpose of fulfilling Licensees obligations in relation to this Agreement.

License Property
Compound means the active drug substance lorazepam (7-chloro-5-(2-chlorophenyl)-3- hydroxy- l ,3-dihydro-2H-1,4..benzodiazepin-2-one) including all salts, esters, complexes, chelates, hydrates, isomers, stereoisomers, crystalline forms, amorphous forms, prodrugs (including all compounds that are metabolized or dissolve into the same active moiety in the body), solvates, metabolites/metabolic precursors, and pegylated form thereof.

Other Compound means diazepam (7-chloro-l-methyl-5-phenyl-l ,3-dihydro-2H-1 ,4- benzodiazepin-2-one). including all salts, esters, complexes, chelates, hydrates, isomers, stereoisomers, crystalline forms, amorphous forms, prodrugs (including all compounds that are metabolized or dissolve into the same active moiety in the body), solvates, metabolites/metabolic precursors, and pegylated form thereof.

Product means the nasal formulation of Product Intermediate incorporated or filled into a Device.

Buccal Formulation means formulations of Product Intermediate for administration by placing in the mouth for absorption through the cheek, the gum or the upper or lower inside lip without swallowing, achieved by means of a muco adhesive, including but not limited to any specific formulation that may be selected for commercialization.

Field of Use
The product is used or useful in the manufacture and use of products containing nanoparticles.

Field means the use as a prescription or over-the-counter pharmaceutical product in humans, specifically excluding diagnostic use.

Licensee acquired global rights to a novel nasal lorazepam formulation for the treatment of emergency seizures in epilepsy patients.

IPSCIO Record ID: 359061

License Grant
Included with this license and collaboration agreement is a license grant upon voluntary termination.

With respect to the applicable Reversion Compounds being terminated, Licensor grants, effective upon such termination, an exclusive even us to Licensor. sub-licensable, worldwide license under the Licensor Reversion Technology to research, develop, import, use, make. have made, offer for sale and sell Reversion Compounds and Reversion Products including as part of a Licensee Combination Therapy in the Field in the Territory.

License Property
Licensors Reversion Technology means Licensor Technology that both was actually used or generated by Licensor or its Affiliates or Sublicensees with respect to the applicable Reversion Compound or Reversion Product, and is necessary to continue development, manufacture or commercialization without unreasonable delay of the applicable Reversion Compound or Reversion Product.

Reversion Compound means NLG919, any Next Generation Compound or any Subsequent Compound.

NLG919 means Licensee’s proprietary small molecule IDO inhibitor known as of the Execution Date as NLG919, or any enantiomer, polymorph, salt form, base, acid, racemate, isomer, diastereomer, tautomer, solvate, hydrate, ester or Known Prodrug thereof.

Next Generation Compound means any Compound other than NLG919 that is invented, by or on behalf of Licensee or its Affiliate, whether solely or jointly, as of the Effective Date or thereafter during the Restriction Period, whether or not pursuant to the Research Plan, that is invented or otherwise the subject of research or preclinical development conducted, by or on behalf of Licensor or its Affiliate or Sublicensee, but excluding the pRED Organization, whether solely or jointly, during the Next Gen Research Term, whether or not pursuant to the Research Plan, the composition of matter, manufacture or use of which is Covered by a Valid Claim of a Licensee Patent or Collaboration Patent; or that is an enantiomer, polymorph, salt form, base, acid, racemate, isomer, diastereomer, tautomer, solvate, hydrate, ester or Known Prodrug of a Compound described above.

Field of Use
Field means any use.

Indication means any separately defined. well-categorized class of human disease, syndrome or medical condition for which a separate MAA may be filed with a Regulatory Authority. Each different tumor type or a different hematological malignancy as classified by cell lineage (e.g., acute lymphoblastic leukemia is a different Indication from chronic myclogenous leukemia) shall be a separate Indication; however each different line of therapy for a particular tumor type or hematological malignancy will not he considered a separate Indication.

IPSCIO Record ID: 344646

License Grant
English Licensor hereby grants to Licensee an exclusive, royalty-bearing licence (with the right to grant sublicenses) under the Licensor Licensed IP to Exploit the Licensor Licensed Compounds and the Licensed Products in the Field in the Territory.

English Licensor hereby grants to Licensee (and its Affiliates and Sublicensees) access to, and a right of reference with respect to, any Regulatory Materials, to the extent Controlled by Licensor at the Commencement Date, for the purposes of Exploiting the Licensor Licensed Compound and Licensed Products in the Field in the Territory. Licensor agrees to execute, acknowledge, and deliver any further documents or instruments and to perform all such other acts as may be reasonably necessary or appropriate in order to effect such right of reference.

License Property
Licensor has discovered and developed a CB1 antagonist compound known as V24343 and owns and controls various data and know how relating thereto.

Licensed Product means any pharmaceutical product containing a Licensor Licensed Compound in any and all forms, presentations, delivery systems, dosages, and formulations.

V24343 means the molecule and structure and any metabolite, salt, ester, hydrate, solvate, isomer, enantiomer, free acid form, pro-drug (including ester pro-drug) form, racemate, polymorph, chelate, stereoisomer, tautomer, resinate or optically active form thereof.

Licensor Licensed IP means any and all Licensor Know How including the Licensor Regulatory Materials and Licensor Licensed Compound Information.

Field of Use
ANEB-001 is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations.

IPSCIO Record ID: 369254

License Grant
Licensor grants to Licensee of the Russian Federation an exclusive right and license or  sublicense, as applicable, to the Licensed Technology to research, develop, make, have made, use, sell, offer for sale and import the Licensed Compound, Licensed Products and Licensed Product Biomarkers for the Field in the Licensee Territory.

This agreement includes a non-exclusive grant back to Licensor from Licensee.

License Property
Licensor develops, manufactures and commercializes products incorporating the proprietary compound known as tivozanib for the treatment of cancer.

Licensed Compound means the chemical compound 1-[2-chloro-4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-3-(5-methyl-1,2-oxazol-3-yl)urea, otherwise known as tivozanib, and any and all pharmaceutically acceptable, acids, bases, esters, isomers, enantiomers, salts, stereoisomers, racemates, tautomers, polymorphs, complexes, chelates, crystalline and amorphous forms, prodrugs, solvates (including hydrates), metabolites and metabolic precursors, whether active or inactive, thereof.

Licensed patents are
Neuropilin-1 as a serum based biomarker;
Quinoline Derivatives and Quinazoline Derivatives having Azolyl Group; and,
Tivozanib Response Prediction.

Licensed Know-how is module 3 of the New Drug Application for tivozanib hydrochloride for the treatment of renal cell carcinoma.  

Licensed Product Biomarker means any and all biomarkers, including metabolite, DNA, RNA and protein profiles, discovered or developed by or on behalf of Licensor or Licensee during the Term that are for use with, including use in clinical testing of or use in any decision whether to prescribe, or relate to, are associated with or are correlated with patient populations who do or do not respond to treatment with, in the case of each, any one or more Licensed Products.

Tivozanib A potent, selective, long half-life vascular endothelial growth factor (“VEGF”) tyrosine kinase inhibitor (“TKI”) of VEGF receptors 1, 2 and 3. The Licensor is evaluating several potential paths for the development of tivozanib, including a second phase 3 trial of tivozanib in refractory renal cell carcinoma, or RCC.

Field of Use
The Field means the diagnosis, prevention and treatment of any disease or condition in humans other than non-oncologic diseases or conditions of the eye.

This agreement purpose is for the development, manufacturing and commercialization of Licensors small molecule vascular endothelial growth factor (YEGF) tyrosine kinase inhibitor tivozanib in the territories of Russia, Ukraine and the Commonwealth of Independent States (CIS), for all indications excluding ocular conditions.

IPSCIO Record ID: 256780

License Grant
The French Licensor hereby grants to Licensee an exclusive (including with regard to Licensor and its Affiliates) license, with the right to grant sublicenses, under the Licensed Patents and the Licensed Know-How to Exploit the Licensed Compounds and the Licensed Products in the Field in the Territory; and a non-exclusive license to use the Licensors Corporate Names solely as necessary for Licensee to perform its obligations and for no other purpose.
License Property
Licensed Patents
4,883,867 – Detection of reticulocytes, RNA or DNA
6,355,631 – Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation
7,652,154 – Method and intermediates for the preparation of derivatives of N (1-benzhydrylazetidin-3-yl)-N-phenylmethylsulfonamide

Licensed Compound means the pharmaceutical compound known as AVE1625 (drinabant), as more specifically described, together with any metabolite, salt, ester, hydrate, solvate, isomer, enantiomer, free acid form, free base form, crystalline form, co-crystalline form, amorphous form, pro-drug form, racemate, polymorph, chelate, stereoisomer, tautomer or optically active form of any of the foregoing.

Field of Use
Field means the therapeutic emergency treatment of Acute Cannabinoid Overdoses in humans by administration of a pharmaceutical product via any parenteral route of administration. The term “Field” excludes the chronic administration of a therapeutic agent, irrespective of the purpose or route of administration.

IPSCIO Record ID: 239024

License Grant
The Licensor of Spain grants to an exclusive, even as to Licensor, license under the Patent Assets and the Licensor Know-How, including the right to grant sublicenses, to develop, make, have made, use, import, offer for sale, promote, market, commercialize, distribute and sell Product in the Territory, and insofar as necessary for the purposes of exercising such rights, to develop, make, have made, use, import, offer for sale, commercialize, distribute and sell Compound.
License Property
The compound is UR-12746 Sodium Salt, meaning UR-12746 (including UR-12715) and UR-12746(S), and any derivative, homolog or analog of any of the foregoing or any isomer, salt, hydrate, solvate, amide, ester, metabolite, or prodrug of any of the foregoing, and any pharmaceutical composition containing any of the foregoing in any pharmaceutically acceptable form.

Licensor possesses significant expertise in the field of antiinflammatory therapeutics, and dersalazine represents the culmination of years of internal research.

Dersalazine is a new chemical entity that combines a well-known anti-inflammatory agent, 5-ASA, with a novel potent agent that acts as a PAF antagonist and an inhibitor of key interleukin cytokines to achieve a synergistic therapeutic effect when compared to the activities of each component separately. Chemical cleavage of dersalazine by colonic bacteria releases the two active compounds for the topical treatment of inflammation in the colon. The 5-ASA molecule contained in dersalazine has known antioxidant properties which may ameliorate the deleterious inflammatory effects ascribed to the overproduction of free radicals.

Field of Use
Dersalazine is a compound in early clinical development to treat Inflammatory Bowel Disease (IBD), which includes ulcerative colitis and Crohn's disease.

IPSCIO Record ID: 372521

License Grant
Licensor grants to Licensee of Germany, an exclusive right and license under the Licensor Patent Rights, the Licensor Know-How and Licensors interest in the Joint Patent Rights and Joint Know-How to research, have researched, develop, have developed, register, have registered, use, have used, make, have made, import, have imported, export, have exported, market, have marketed, distribute, have distributed, sell and have sold PET Ligand and Products in the Field in the Territory.

Licensee has the right to develop and commercialize the PET Ligand as set forth.

License Property
Licensor has discovered proprietary compounds of the NMDA class and possesses proprietary intellectual property rights relating thereto, including the Licensor Patent Rights.

Licensor patents and technology relate to Imidazole Derivatives.  The invention relates to novel Imidazole Derivatives which are NMDA receptor subtype specific blockers, useful in the treatment of acute forms of neurodegeneration (stroke, brain trauma) and  of chronic forms of neurodegeneration ( Alzheimers disease, Parkinson, Huntingtons disease, ALS).

The products covered by the License Agreement are xO0678867; xO0693960; xO4378536; xO4394127; xO0631908; and, xO0717626.

The term Compound shall mean any of xO-0631908, xO-0678867, xO-0693960, xO4378536, x0-4394127, xO-0717626 and other compound structures Covered by the patent applications and patents for NMDA-2B receptor antagonists listed to the Agreement, including their salts, polymorphs, crystal forms, esters, hydrates, solvates, chelates, clathrates, metabolites that are NMDA-2B receptor antagonists, pro-drugs, isomers and enantiomers.

The term EVT 101 shall mean xO-4394127.

The term EVT 103 shall mean xO-0717626.

The term PET Ligand shall mean a Compound, with the exception of EVT 101 and EVT 103,
appropriately labelled for use in positron emission tomography for the specific labelling of NMDA NR2B subunit containing receptors in vivo.

Field of Use
The patent portfolio covers NMDA receptor NR2B subtype selective antagonists (the
EVT 100 family) for the treatment of a variety of CNS disorders such as Alzheimer’s disease, neuropathic pain and Parkinson’s Disease.

IPSCIO Record ID: 26543

License Grant
Licensor hereby grants to Licensee an Exclusive License in the Territory, under Licensort Technology, for all Pharmaceutical Uses, with the right to grant sublicenses to (i) research, develop, make or have made, Compound A, Compound B and Product(s); (ii) apply for and obtain Regulatory Approvals, all as may be required to manufacture and commercialize Product(s); and (iii) register, use, import/export, market, offer to sell and sell, Product(s) and Compound A and Compound B.
License Property
COMPOUND A means the compound known as ABT-773, its enantiomers, racemates, isomers and any pharmaceutically acceptable salt or complex thereof, in its current and any other formulation, and including any Prodrugs and active metabolites, whether made before or after the Effective Date.

COMPOUND B means the compound known as ABT-210, its enantiomers, racemates, isomers and any pharmaceutically acceptable salt or complex thereof, in its current and any other formulation, and including any Prodrugs and active metabolites, whether made before or after the Effective Date.  Commercialize cethromycin, a novel ketolide antibiotic in Phase III clinical development for the treatment of respiratory tract infections. Ketolides, a new class of antibiotic to treat respiratory tract infections, have demonstrated strong activity against bacteria that are resistant to many currently marketed antibiotics. Following the offerings, we intend to conduct two pivotal Phase III clinical trials of cethromycin for the treatment of mild-to-moderate community acquired pneumonia.

Field of Use
The rights granted apply to Pharmaceutical Uses.

IPSCIO Record ID: 279309

License Grant
Licensor grants to the Licensee of Puerto Rico an exclusive license, with the right to sublicense, under the Licensor Compound Patents, Other Licensor Patents and Licensor Know-How, to research, develop, make, have made, use, sell, have sold, offer for sale and import the Compound and Products in the Field in the Territory.

Licensor grants a non-exclusive, royalty free license to use Licensors corporate Trademarks solely for purposes of Commercializing Products, which license shall terminate upon the expiration or earlier termination of this Agreement for any reason.

License Property
Licensor is engaged in manufacturing, research and development of pharmaceutical products and is currently engaged in the development of AGI-1067.  

Compound means AGI-1067, which is chemically defined as Butanedioic acid, including its pharmacologically acceptable salts, solvates, hydrates, hemihydrates, polymorphs, metabolites; free base forms, pro-drugs, esters, tautomers and if applicable, any isomers, stereoisomers, racemates, enantiomers and all optically active forms thereof.

AGI-1067 is a novel vascular protectant, anti-inflammatory drug and mild antiplatelet agent for treatment of atherosclerosis.
Atherosclerosis is a disease in which the inside of an artery narrows due to the build up of plaque.

Field of Use
Licensee is engaged in the research, development, manufacture and marketing of pharmaceutical products.  AGI-1067 is designed to benefit patients with coronary heart disease (CHD), which is atherosclerosis of the blood vessels of the heart.   Atherosclerosis is a common disease that results from inflammation and the buildup of plaque in arterial blood vessel walls.

IPSCIO Record ID: 87659

License Grant
The license to be granted by Licensor to Licensee is a royalty-bearing license under all applicable patent and other proprietary rights of Licensee, including without limitation rights under the Technology and Licensee’s interest in the New Inventions and Joint Inventions to develop, make, have made, use, sell, offer to sell, import and export (or otherwise commercialize and exploit) the Products in the Field in the Territory.

Subject to the Right of First Refusal and Option below, Licensor shall not license to any third party, and hereby grants an exclusive option to Licensee to license, the Licensor IP Rights to develop, make, have made, use, sell, offer to sell, import and export (or otherwise commercialize and exploit) naloxone for treatment or prevention of opioid overdose in the Territory.

License Property
Product Pharmaceutical formulations containing the Compound as an active ingredient and the Excipient.

Compound Naloxone or Option Compound and any metabolite, salt, ester, hydrate, anhydride, solvate, isomer, enantiomer, free acid form, free base form, crystalline form, co-crystalline form, complexes, amorphous form, pro-drug (including ester pro-drug) form, racemate, polymorph, chelate, isomer, tautomer, or optically active form of the foregoing.

Option Compound Naltrexone and nalmephene/ nalmefene.

Naloxone is a medication used to block the effects of opioids, especially in overdose.[1] Naloxone may be combined within the same pill as an opioid to decrease the risk of misuse.

Naloxone blocks or reverses the effects of opioid medication, including extreme drowsiness, slowed breathing, or loss of consciousness. An opioid is sometimes called a narcotic.

Field of Use
This agreement pertains to the treatment or prevention of any disease, disorder, state, condition or malady in humans except in the Opioid Field, provided that upon election of Opiant in writing and payment of the Option Fee, the “Field” shall include the Opioid Field.

Naloxone is used to treat a narcotic overdose in an emergency situation. This medicine should not be used in place of emergency medical care for an overdose.

Naloxone is also used to help diagnose whether a person has used an overdose of an opioid.

IPSCIO Record ID: 299247

License Grant
Licensor grants
—  an exclusive license, with right to sublicense through one or more tiers, under the Licensed Patent Rights to make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, import and have imported Products in the Field.  
—  an exclusive license, with right to sublicense through one or more tiers, under the Know-How, to make, have made, use, have used, sell, have sold, offer  for sale, have offered for sale, import and have imported Products in the Field and a nonexclusive license to any other know-how existing on the Closing Date and provided to Licensee which is useful to develop or commercialize the Products in the Field.
License Property
Licensor has research regarding small-molecule immune response modifier compounds and other small molecule compounds, some of which act by stimulating basic immune cell receptors known as toll-like receptors  (TLRs) 7 and/or 8.

The Assigned Patent Rights and Licensed Patent Rights include any prodrug or any hydrate, solvate, conjugate, salt, ester, stereoisomer or polymorph of such compound or prodrug.

Field of Use
The Field means the diagnosis, treatment, mitigation, or prevention of any disease or condition in humans or animals, other than uses that are within the Excluded Fields. The Excluded Fields are
—  the treatment, topically or systemically, of diseases of the cervix or vaginal tract caused by human papilloma virus (HPV) infection, including cervical high risk·HPV infection and cervical dysplasia, and the treatment of cervical malignancy by topical application to the cervix, but not including systemic treatments of cervical malignancy;
—  any use of imiquimod, 848 (resiquimod}, 850 (sotirimod), and the alkyl ureas S-32913 and S-33005, including any acid, ester, salt, amide, prodrug, polymorph, enantiomer or isomer thereof, and any pharmaceutical product containing such compounds, in the Topical Field, which means the treatment, mitigation, or prevention of a disease or condition by topical application (e.g., dermatological, pulmonary or vaginal) of the drug to the skin or mucosa (e.g., bronchialand vaginal tissue) of a patient by, for example, but not limited to, gels, creams, ointments, foams, lotions, salves, roll-ons, powders, sprays, or inhalants, like aerosols such as for asthma and allergic rhinitis;
—  marketing the 3MIRM Compounds 852 (N-[4-(4-amino-2-ethyl-1Himidazo[4;5 c]quinoliri-1-yl)butyl]methanesulfonamide) and/or 854 (N-{2-[4-amino-2 ( ethoxymethyl)-1 H-imidazo[ 4, 5-c]quinolin-1-yl]-1 , 1-d imethylethyl}methanesulfonamide)  (including any acid, ester, salt, amide, pro-drug, polymorph, enantiomer or isomer thereof, and.any pharmaceutical product containing such compounds) for the indications of genital warts, common warts, basal cell carcinoma, actinic keratosis, tattoo removal, or photoaging; and
— any use of the 3M Compounds as a Vaccine Adjuvant.

IPSCIO Record ID: 245949

License Grant
Licensor hereby grants to Licensee and its Affiliates an exclusive license (including as to Licensor), with the right to grant sublicenses, under the Licensed Patent Rights (subject to Licensors retained right set forth), solely for the purposes of research, making, having made, using, developing, registering, offering to sell, selling, importing and exporting and distributing Products and Compounds in the Field in the Territory. Licensor retains the nonexclusive right to make and use Compounds for internal research purposes only, provided, however, under no circumstances shall Licensor’s retained right be used for administering the Compounds to animals or humans, nor to provide Compounds to Third Parties.

Licensor hereby grants to Licensee and its Affiliates a nonexclusive license, with the right to grant sublicenses, to the Licensed Know-How solely for the purposes of research, making, having made, using, developing, registering, offering to sell, selling, importing and exporting and distributing Products and Compounds in the Field in the Territory.

Licensor hereby grants to Licensee and its Affiliates an exclusive license (including as to Licensor), with the right to grant sublicenses, under the Aplindore Licensed Know-How (subject to Licensor’s retained right set forth below) solely for the purposes of research, making, having made, using, developing, registering, offering to sell, selling, importing and exporting and distributing Products and Compounds in the Field in the Territory. Licensor retains the nonexclusive right to make and use Compounds for internal research purposes only, provided, however, under no circumstances shall Licensor’s retained right be used for administering the Compounds to animals or humans, nor to provide Compounds to Third Parties.

License Property
Product means a pharmaceutical product, formulation or preparation for sale and therapeutic use in humans containing one or more Compounds as a pharmaceutically active ingredient(s).

Compounds means Aplindore and pharmaceutically acceptable salts or complexes thereof, and all salts, solvates, crystal forms, polymorphs, chelates, non-covalent complexes, hydrates, enantiomers, and racemates thereof.

Aplindore means the compound having CAS Registry Number 189681-71-8 and known as aplindore; aplindorum; aplindor; palindore; palindorum; palindor; 8H-1,4-dioxino[2,3-e]indol-8-one, 2,3,7,9-tetrahydro-2-[[(phenymethyl)amino]methyl]-,2(S)-,(2E)-2-butenedioate; (2S)-2-[(benzylamino)methyl]-2,3,7,9-tetrahydro-8H-1,4-dioxino[2,3-e]indol-8-one (E)-butenedioate; or DAB-452.

Aplindore was initially developed by the Licensor for schizophrenia and has been studied in six Phase I and Phase II clinical trials involving over 100 healthy volunteers and over 100 schizophrenic patients. The drug demonstrated excellent brain receptor occupancy and pharmacologic activity at low doses, but proved inappropriate for the treatment of this disease at the dose range tested.

Field of Use
Aplindore is a drug which acts as a partial agonist selective for the dopamine receptor D2. It is being developed by Licensee as a treatment for Parkinson's disease and restless legs syndrome.  Restless legs syndrome (RLS) is a condition that causes an uncontrollable urge to move your legs, usually because of an uncomfortable sensation. It typically happens in the evening or nighttime hours when you're sitting or lying down. Moving eases the unpleasant feeling temporarily.

Licensee expects to commence Phase II trials in Parkinson's disease and restless legs syndrome (RLS) with Aplindore during 2007, following the manufacture of clinical supplies.

IPSCIO Record ID: 344504

License Grant
The Licensor of Portugal grants an exclusive license under the Licensor Patents and Know-How to use, market, distribute, import, commercialize, offer for sale and sell the Licensed Products under the Licensor Trademarks within the Field and Territory either directly on its own and/or through its permitted Affiliates, sublicensee and/or distributors.

Licensor grants an exclusive license to use the Licensor Trademarks in connection with any Licensed Products that Licensee uses, markets, promotes, distributes, imports, commercializes, offers for sale or sells within the Field and Territory either directly on its own and/or through its Affiliates, sublicensee, and/or distributors.

Licensor grants a non-exclusive license to use the Licensor Logo on all packaging materials, promotional materials and documents that are used by Licensee either directly on its own and/or through its sublicensee, contractors or distributors in connection with the development, promotion, marketing, offer for sale, sale, import and commercialization of the Licensed Products.

Licensor grants a worldwide, non-exclusive license, without any right to sub-license, under the Licensor Patents and Licensor Know-How to develop or have developed on its behalf, Licensed Products for use and sale within the Field and the Territory,

License Property
Licensor Controls the Licensor Patents and Licensor Know-How relating to its proprietary compound xxx 2-093 and its use in the treatment of human diseases and conditions including, without limitation, epilepsy;

Licensed Products means the xxx 2-093 Product and all other products, including any current or future dosages, formulations, improvements and/or delivery modes comprising xxx 2-093 and all possible metabolites, salts, hydrates, polymorphs, crystalline forms, solvates and prodrugs thereof, including any present and future combination products containing xxx 2-093 or a metabolite, salt, hydrate, polymorph, crystalline form, solvate or prodrug thereof, as one of the active ingredients.

xxx 2-093 means Licensors proprietary compound (S)-(-)-10-acetoxy-10,11- dihydro-SH-dibenz/b,f/azepine-5-carboxamide, known under the International Nonproprietary Name (INN) Eslicarbazepine Acetate.

Licensor Trademarks mean ERELIB' and PAZZUL.

The logo is BIAL.

Field of Use
The license is for the anti-epileptic compound, BIA 2-093, which we now refer to as SEP-0002093.

SEP-0002093 is a new chemical entity which is intended to offer patients suffering with partial epilepsy additional control of their seizures and improved quality of life. Licensor has completed a Phase III program in Europe for the adjunctive treatment of epilepsy.

The Field means all human and non-human diagnostic, prophylactic and therapeutic uses of the Licensed Products for adjunctive use in Adult Partial Epileptic Seizures and any and all new indications, including but not limited to Epilepsy Monotherapy, Trigeminal Neuralgia, Diabetic Neuropathic Pain and Post-herpetic Neuralgia.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.